Events of Default | 19-Feb-2024 | 10:30 | RNS |
Further re: Exercise of options | 31-Jan-2024 | 07:00 | RNS |
BEXMAB Insights into Patient Profiles | 25-Jan-2024 | 07:00 | RNS |
Exercise of options - Issue of equity | 19-Jan-2024 | 13:00 | RNS |
First Patient Dosed in Ph 2 of the BEXMAB Trial | 09-Jan-2024 | 07:00 | RNS |
Faron’s Financial Calendar fo... | 22-Dec-2023 | 07:00 | RNS |
Phase 1 BEXMAB data presented at ASH | 11-Dec-2023 | 07:00 | RNS |
Grant of options | 04-Dec-2023 | 07:00 | RNS |
Faron Initiates Phase 2 Part of BEXMAB Study | 06-Nov-2023 | 08:13 | RNS |
Faron Initiates Phase 2 Part of BEXMAB Study | 06-Nov-2023 | 07:00 | RNS |
Manager's transactions | 27-Oct-2023 | 13:00 | RNS |
Exercise of options | 27-Oct-2023 | 07:15 | RNS |
Results of Placing | 27-Oct-2023 | 07:00 | RNS |
Proposed Issue and Placing | 26-Oct-2023 | 16:30 | RNS |
Faron Announces Positive BEXMAB Study Update | 11-Oct-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 131.25p |
Change Today | 3.75p |
% Change | 2.94 % |
52 Week High | 350.00p |
52 Week Low | 117.50p |
Volume | 188 |
Shares Issued | 72.01m |
Market Cap | £94.51m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 1 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
11:31 | 4 @ 132.75p |
09:44 | 18 @ 132.75p |
09:18 | 83 @ 121.50p |
09:15 | 83 @ 121.50p |
CEO | Markku Jalkanen |
Chair | Tuomo Pätsi |
You are here: research